However, sub-group analysis showed that the anti-VEGF agents rechallenge marginally improved OS in elderly (aged ≥ 65 years) HCC patients who previously treated with sorafenib (HR 0.83, 95% CI: 0.68–1.01, p = 0.061), while no survival benefit was obtained in elderly HCC received first-line anti-VEGF treatment (HR 1.19, 95% CI: 0.74–1.90, p = 0.47). Here, VEGFA is linked to hepatocellular carcinoma.